This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Treatment is with synthetic human growth hormone, although other additional hormones may also be indicated.

Treatment with growth hormone in a child with growth hormone deficiency should be started as soon as possible after diagnosis.

There is evidence that treatment with synthetic growth hormone in a children with growth hormone deficiency:

  • produces a final height gain of 25-30cm (1)
  • almost 90% of children with growth hormone deficiency treated with synthetic growth hormone achieve an adult final height within the genetically determined target height range (2)

Growth hormone received a NHS license for use in the growth hormone deficient adult (3)

Reference:

  • The British Society for Paediatric Endocrinology and Diabetes and the Royal Colleges of Paediatrics and Child Health. Submission of evidence for the National Institute of Clinical Excellence health technology appraisal: the use of human growth hormone in children.
  • Thomas M et al. Final height in children with idiopathic growth hormone deficiency treated with recombinant human growth hormone: the Belgium experience. Horm Res 2001; 55:88-94.
  • Update (5/11/97), p.652-6.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.